Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait

Authors

Ahmed Swidan, Nephrology Department, Dar Elshifa Hospital, Kuwait City, Kuwait,Faculty of Medicine, Alexandria University, Alexandria, Egypt
Gihan Hamdy Elsisi, HTA Office, LLC, Cairo, Egypt,Economics Department, American University in Cairo, Cairo, Egypt
Mohamed M. Ibrahim, Jaber Al-Ahmed Armed Forces Hospital - Department of Medicine - Kuwait Ministry of Defence, Kuwait City, Kuwait
Mohammad Aljazzar, Market Access AstraZeneca, AstraZeneca, GCC, Dubai, UAE

Second Author's Department

Economics Department

Document Type

Research Article

Publication Title

Journal of Medical Economics

Publication Date

2-14-2023

doi

10.1080/13696998.2023.2174749

First Page

271

Last Page

282

Recommended Citation

APA Citation

Swidan, A. Elsisi, G. Ibrahim, M. & Aljazzar, M. (2023). Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait. Journal of Medical Economics, 26, 271–282. 10.1080/13696998.2023.2174749
https://fount.aucegypt.edu/faculty_journal_articles/5544

MLA Citation

Swidan, Ahmed, et al. "Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait." Journal of Medical Economics, vol. 26, 2023, pp. 271–282.
https://fount.aucegypt.edu/faculty_journal_articles/5544